Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33707180.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0254 and PMC identifier 12128293.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The single-agent activity of MEK inhibitors in MAPK or CDK4/6 inhibitors in cyclin pathway aberrant tumors has been limited. The combination of trametinib and palbociclib demonstrates safety, tolerability, and clinical activity in a histology-independent manner, representing a therapeutic approach for patients harboring co-occurring aberrations.<i>See related article by Kato et al., p. 2792</i>.
Medical subject headings
- Neoplasms